Antibody-drug conjugates (ADCs) represent a potent and innovative approach in the treatment of various cancers. As of May 2024, there are 13 globally approved ADC drugs, with over 100 candidates undergoing clinical trials. However, the creation of ADCs goes beyond a simple combination; it involves a complex process where factors such as the target, antibody, payload, and linker must be carefully considered. Moreover, due to their structural diversity and complexity, ADCs encounter unique challenges in formulation, manufacturing, and quality control. This poster covers the five critical considerations in ADC drug design and the comprehensive ADC development solutions offered by Sino Biological. Download now to learn more.